| 期刊論文| 1. | Wax, Paul M.(1995)。Elixirs, diluents, and the Passage of the 1938 Federal Food,Drug and Cosmetic Act。J ANN INTERN，122(6)，456-461。   | | 2. | Colgrove, James(2007)。Immunity for the People: The Challenge of Achieving High Vaccine Coverage in American History。Public Health Rep.，122(2)，248-257。 | | 3. | Nasr, Alexander、Lauterio, Thomas J.、Davis, Matthew W.(2011)。Unapproved drugs in the united states and the food and drug administration。Advances in Therapy，28(10)，842-856。 | | 4. | Sheridan, W. P.、Wolf, M.、Lusk, J.、Layton, J. E.、Souza, L.、Morstyn, G.、Dodds, A.、Maher, D.、Green, M. D.、Fox, R. M.(1989)。GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION。The Lancet，334(8668)，891-895。 | | 5. | Pivarnik, Greg(2014)。Cells as Drugs?: Regulating the Future of Medicine。AM. J.L. & MED.，40，298-321。 | | 6. | Chirba, Mary Ann、Garfield, Stephanie M.(2011)。FDA Oversight of Autologous Stem Cell Therapies: Legitimate Regulation of Drugs and Devices or Groundless Interference with the Practice of Medicine?。J. HEALTH & BIOMEDICAL L.，7，233-270。 | | 7. | Epstein, Richard A.(2013)。The FDA's Misguided Regulation of Stem Cell Procedures: How Administrative Overreach Blocks Medical Innovation。LEGAL POL'Y REP.，17。 | | 8. | Caplan, Arnold I.、West, Michael D.(2014)。Progressive Approval: A Proposal for a New Regulatory Pathway for Regenerative Medicine。STEM CELLS TRANSLATIONAL MED.，3。 | | 9. | Centeno, C. J.(2008)。Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells。Pain Physician，11。 | | 10. | Hudson, Kathy L.、Collins, Francis S.(2017)。The 21st Century Cures Act - A View from the NIH。N Engl J Med，376，111-113。 | |